<DOC>
	<DOCNO>NCT01227577</DOCNO>
	<brief_summary>`` This single-arm , open-label , multi-center study complete molecular response ( CMR ) adult patient newly diagnose Philadelphia chromosome positive ( Ph+ ) chronic myelogenous leukemia chronic phase ( CML-CP ) . The study design evaluate early deep molecular response 4 year nilotinib treatment . The primary end point Rate confirm CMR newly diagnose Philadelphia chromosome positive CML-CP patient . ''</brief_summary>
	<brief_title>CMR Rate Newly Diagnosed CML-CP Patients Treated With Nilotinib</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>Patients Ph+ CMLCP within 3 month diagnosis . Male female patient ' â‰¥ 18 year age . Patients must adequate end organ function . Previously document T315I mutation . Other CML treatment exclusion criterion follow exception : While await study start , patient may treat anagrelide ( treatment duration limit ) , hydroxyurea ( treatment duration limit ) , and/or 14 day supply tyrosine kinase inhibitor ( TKI ) approve FDA frontline treatment . Patients take TKI prior study entry must least one day washout last dose medication recover side effect therapy . Impaired cardiac function define protocol . Patients contraindication receive nilotinib , include concomitant medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>CML</keyword>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>Leukemia</keyword>
	<keyword>CML-CP</keyword>
	<keyword>Nilotinib</keyword>
</DOC>